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Abstract: 
Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) is single-
stranded, positive-sense RNA virus in the family Arteviridae, order Nidovirales. PRRSV 
began circulating in the U.S swine population in the 1980’s and since then becoming the 
most economically significant disease of swine herds.  PRRSV is now disseminated 
worldwide causing great economic losses to pork industries.  PRRSV single-stranded 
RNA genome is 15 kb in length.   The genome encodes 9 open reading frames (ORF1a, 
ORF1b, ORF2a, ORF2b and ORFs 3 through 7). ORFs 1a and 1b encode for 13 non-
structural proteins (nsp) that are suggested to be involved in transcription and viral 
genome replication. The exact role of non-structural proteins in PRRSV cycle is still 
unknown. Moreover, there is a limited availability of reagents, such as antibodies 
against these non-structural proteins, that further limits their study. To overcome that 
limitation, the gene encoding for non-structural protein 12 (nsp-12) was synthesized 
using the polymerase chain reaction (PCR) and cloned in-frame into a plasmid vector 
(pRSET A) to create the plasmid construct pRSETAnsp-12. After transforming 
Escherichia coli with pRSETAnsp-12, individual colonies that grew in the presence of 
ampicillin were selected, cultured in terrific broth-ampicillin media, and plasmid DNA 
extracted to evaluate for the presence and fidelity of the nsp-12 gene by means of 
agarose gel electrophoresis separation and sequencing. DNA plasmids harboring a 
correct copy of the gene were used to express nsp-12 protein in BL21 competent 
Escherichia coli cells. After growth of BL21 transformants in “Magic media”®, 
expression of nsp-12 was assessed by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) separation followed by Coomassie blue staining and western blot detection 
using an anti-His monoclonal antibody.  PRRSV nsp-12 was then purified by metal 
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affinity chromatography. Purified nsp-12 protein will be used to produce an anti-nsp-12 
polyclonal antibody serum in rabbits for further study the functions of this protein. 
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Need for Research 
 Porcine Reproductive and Respiratory Syndrome Virus is currently one of the 
most economically devastating diseases affecting the swine industry.  The virus belongs 
to the family Arteriviridae and first appeared in North America in 1987, followed by 
Western Europe in the 1990s. Porcine Reproductive and Respiratory Virus Syndrome 
infection induces a wide variety of clinical signs, notably reproductive failure in sows and 
respiratory disease in swine of all ages.  PRRSV genetic determinants of virulence are 
still poorly understood. 
The virus is readily transmitted via the respiratory route and infects primarily cells 
of the immune system.  There are few, if any, effective treatments. While there are two 
main strains of the virus, considerable genetic variation among individual isolates, when 
used as vaccines, fail to induce a cross-protective immune response.  This genetic 
variation is one of the main obstacles in producing vaccines that can confer 
heterologous protection.   
The overall goal of the laboratory is to identify PRRSV genetic determinants 
affecting virus-host interactions and virus virulence.  To accomplish this goal and better 
elucidate the interactions of PRRSV proteins with host cellular proteins, there is a need 
for reagents that would allow detection of those interactions. Thus, production of 
reagents such as antibodies to detect specific viral proteins is of paramount importance 
for these studies. The objective of the work described here was to express and purify 
PRRSV nsp-12 protein, one of the proteins in the virus replication complex. In turn this 
purified viral protein will be used for producing antibodies. 
  
8 
 
Review of the literature 
Arteriviruses 
 Porcine Reproductive and Respiratory Syndrome Virus is a member of the virus 
family Arteriviridae, which also includes Equine arteritis virus (EAV), lactate 
dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV).  
These viruses are distinguished by their structure, ability to manifest in a persistent 
state of infection, and an overall similar genome organization (Snijder & Meulenberg, 
2001). The arteriviruses also have a genome organization and mechanism of protein 
expression similar to that of the coronaviruses, especially of the replicase genes 
encoding for the non-structural proteins.  Arteriviruses and coronaviruses were grouped 
into the order Nidovirales based on this correlation, as well as the presence of unique 
subgenomic (sg) messenger ribonucleic acids (mRNAs) (Snijder & Meulenberg, 2001).  
Equine arteritis virus was fully sequenced in 1991, and this virus has provided a model 
for arterivirus research.  The viruses are easily inactivated by detergents, high or low 
pH, and high temperatures.  
 Arteriviruses virions are enveloped, spherical in shape, small, with a diameter 
between 40 to 60 nanometers (nm).  The surface of the virus is smooth with few notable 
projections (envelope glycoproteins).  The viral nucleocapsid is surrounded by a lipid 
bilayer envelope.  The RNA positive-sense genome, with lengths between 12.7 
kilobases (kb) to 15.7 kb, is surrounded by the nucleocapsid, which is situated between 
a lipid bilayer containing a relatively large number of envelope proteins (Snijder & 
Meulenberg, 2001).  Of these proteins there are usually two structural components and 
several glycoproteins (Snijder & Meulenberg, 2001).  
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History 
Porcine Reproductive and Respiratory Syndrome first appeared in North America 
in 1987, and was then found in Western Europe in the 1990s (Albina, 1997). However, 
retrospective studies revealed that PRRSV had appeared in Canada as early as 1979 
and the US in 1985.  This information was gathered in the early 1990s when diagnostic 
assays revealed that PRRSV had spread almost universally to every region in which 
swine were domesticated.  The virus was isolated in the Netherlands and termed the 
Lelystad Virus, and then in the US where it was called Swine Infertility and Respiratory 
Syndrome (SIRS) (Zimmerman, 2006). 
Clinical signs/epidemiology 
Porcine Reproductive and Respiratory Syndrome Virus can induce a variety of 
clinical signs and presentations in infected swine.  The severity and the extent of clinical 
signs often depend on the physiological state of affected animals, including factors such 
as age, sex and reproductive status.  Furthermore, PRRS sometimes becomes endemic 
in a herd and infects swine of all ages, and all may exhibit different clinical signs.  This 
makes clinical diagnosis difficult (Zimmerman, 2006).  Some of the most common 
symptoms are fever, anorexia, reproductive failure, blue ears, pneumonia and 
respiratory disease, and secondary bacterial infection (Rossow, 1998). The initial onset 
of PRRS in a herd is usually characterized by anorexia in a large percentage of swine of 
all ages, which can last up to five days.   This anorexia spreads slowly throughout the 
herd as the virus is transmitted, leading to the term “rolling inappetance” (Zimmerman, 
2006).  Symptoms in sows include spontaneous abortions, late-term abortions 
(including fresh stillborn piglets as well as mummified piglets), and small, weak offspring 
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though the sow may not appear sick (Zimmerman, 2006).  Boars experience anorexia 
and reproductive failure due to infection of reproductive organs. The virus can spread to 
sows through infected semen. Young and grower pigs typically experience anorexia and 
may show some degree of reduction of average daily weight gain (Zimmerman et al., 
2006). PRRSV causes lesions in target organs during replication swine.  Consistently 
these are pneumonia and enlarged lymph nodes, and abortions that usually follow 
microscopic lesions in lungs and reproductive tissues (Zimmerman, 2006).   
Pathogenesis 
Porcine Reproductive and Respiratory Syndrome Virus causes disease in a 
variety of ways by affecting different organ systems in swine.  After the virus enters the 
host, it preferentially infects and productively replicates in alveolar macrophages. 
Important to note is that PRRSV can also infect and replicate within spermatogenic cells 
in boars resulting in contamination of semen. 
PRRSV enters susceptible host cells via endocytosis, and after productive 
replication the virus progeny exits infected cells via nucleocapsid budding from cellular 
membranous structures (i.e: the endoplasmic reticulum or the Golgi apparatus) and 
subsequent fusion of these vesicles with the cellular membrane (Zimmerman, 2006).  
After primary replication, a state of viremia is achieved in infected animals.  PRRSV can 
then effectively spread to different organ systems within the host.  Replication of 
PRRSV within host cells often results in cell death via apoptotic pathways that also may 
affect proximal uninfected cells (Zimmerman, 2006).  The effect of apoptosis induced by 
PRRSV in infected tissues on virus pathogenesis is not clearly understood. 
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PRRSV infection results in a secretion of cytokines from infected cells, including 
interferon-gamma (IFN-γ), tumor necrosis factor alpha (TNF-α), and interleukins (IL) 1, 
6, 9, 10, and 12.  These pro- and anti-inflammatory cytokines trigger the initiation of the 
host immune response aimed to eliminate PRRSV infection, but can also have negative 
effects by inducing inflammation of infected organs (Zimmerman, 2006) and even 
growth retardation (Hollis, 1993).  The role of these cytokines in the pathogenesis of 
PRRSV is not clear. 
Porcine Reproductive and Respiratory Syndrome Virus has a marked effect on 
both infected and uninfected fetuses carried by an infected dam.  Rowland, 2010; 
studied PRRSV replication in fetuses of dams infected late in gestation.  The authors 
observed that both infected and uninfected fetuses displayed signs of PRRSV due to 
maternal infection, including growth retardation and decreased amniotic fluid.  In that 
study it was observed that the primary site of PRRSV replication in the fetus was the 
thymus.  The lymph nodes of infected fetuses resembled lymph nodes that had been 
activated by antigens, meaning that the fetuses mounted an immune response to the 
virus. This observation was supported by the detection of increased cytokine gene 
expression in infected fetuses, including TNF-α and IFN-γ (Rowland, 2010).  The 
negative impact of this immune response will be discussed later in this thesis. 
Although significant progress has been made on understanding the effects of 
PRRSV infection in swine, the genetic determinants of virulence, attenuation, and host 
range are yet to be elucidated. 
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Transmission 
One of the primary issues plaguing swine producers is the high transmissibility of 
PRRSV within and between herds.  The virus is readily infectious and is therefore very 
difficult to prevent the spread of disease.  The most prevalent method of transmission is 
the respiratory route (Snijder & Meulenberg, 2001).  Contact between pigs in which 
nasal secretions, urine or feces are transferred is one way the virus spreads.  Since 
feces are a mode of transmission, fecal matter used in fertilizer can also promote 
PRRSV spread (Albina, 1997).  Aerosolized particles of the virus can also travel over 
short distances, especially during the winter months (Albina, 1997). PRRSV can be 
shed via semen in the absence of viremia and in the presence of anti-PRRSV 
antibodies (Christopher-Hennings, 1995, 2001). The virus most likely infects the 
reproductive tissue via macrophages and monocytes. Boars can shed virus in semen 
for up to 90 days (Christopher-Hennings ,2001) post-infection, generating a serious 
problem for artificial insemination centers. 
Kang, 2010; conducted a study investigating the transmissibility of PRRSV from 
sows to nursing piglets.  Evidence from this study confirmed that PRRSV is localized in 
mammary tissue (in addition to other tissues including the lung, lymph node, spleen 
liver, and tonsils).  However, PRRSV is not found in the epithelial cells of the mammary 
gland, which would allow the virus to pass directly into the milk.  Despite this 
characteristic, the virus is indeed found in the milk of sows due to infection of the tissues 
listed above and subsequent release into the milk via immune cells, an indirect 
pathway.  Viral particles and viral antigens are both detected in milk from infected sows, 
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but it is unclear whether the amount of PRRSV present is sufficient to infect a suckling 
piglet (Kang, 2010).   
Effect of PRRSV on swine growth and development 
Porcine Reproductive and Respiratory Syndrome Virus is, as stated earlier, the 
most economically significant disease currently affecting the swine industry.  This is due 
to the fact that PRRSV impacts negatively on swine fertility and swine growth, which are 
the foremost factors in the economical gain.  PRRSV impacts fetal growth and can lead 
to abortions and stillbirths and decreases weight gain in pregnant gilts.  In grower pigs, 
economic losses derive from decreased appetite, diminished food intake, and delayed 
growth of infected swine. 
Lewis, 2010; conducted a study investigating the effect of PRRSV infection on 
pregnant gilts and grower pigs.  They found that PRRSV infection decreases the weight 
gain of both pregnant gilts and growing piglets, in some cases halting weight gain 
altogether. Furthermore, infection resulted in a decreased litter size in the pregnant gilts.  
Interestingly, Lewis et al. also found evidence that certain breeds, specifically Landrace, 
may show some tolerance to infection, as Landrace gilts and growers used in this study 
did not experience the same amount of weight gain suppression as cross-bred pigs. 
As stated earlier, infection with PRRSV results in an immune response from the 
host, including the release of cytokines. Infected adults and fetuses are capable of 
mounting an immune response to the virus (Rowland, 2010).  Evidence suggests that 
certain cytokines are responsible for the anorexia observed in many diseases (Hollis 
1993).  For instance, IL-1β and TNF-alpha are both produced in response to PRRSV 
infection, and both cytokines decrease feed intake due to an effect resembling that of 
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fibroblast growth factor (FGF). FGF is released after feeding and suppresses appetite 
by acting as a satiety factor on the hypothalamus, and IL-1β and TNF have a degree of 
amino acid sequence identity with FGF (Oomura, 1988). In addition, IL-1α has been 
shown to decrease water and food intake when injected both into the brain and the 
peritoneum of rats.  Futhermore, IL-1 inhibits gastric emptying and acid secretion, which 
likely compounds its satiety effects (Hollis, 1993).  Meanwhile, TNF-alpha causes a 
variety of metabolic effects, including dehydration, lipolysis, insulin resistance (which 
would also account for a decrease in appetite), and protein turnover and loss (Hollis, 
1993).  All of these effects can contribute to a decrease in growth just due to a lack of 
nutrient intake. It is important to notice that undernourishment also has a marked effect 
on the somatotropic axis that controls growth.  Specifically, undernourishment 
decreases concentrations of insulin-like growth factors (IGFs), which stimulate growth, 
and increases concentrations of IGFBPs, which block the action of IGFs.  Fetal 
development is similarly compromised due to the immune response in infected fetuses, 
but fetuses and neonates are at risk due to the symptoms of the infected dam.  As 
stated earlier, pregnant gilts also exhibit increased anorexia and decreased weight gain, 
making less energy available for their litters (Lewis, 2010).  Infected dams also may 
pass infection to uninfected neonates through their milk (Kang, 2010), leading to the 
same sort of growth retardation already explained.  The decrease in milk production in 
infected mothers in response to their decreased IGF concentration is also detrimental to 
neonatal development as it can contribute to undernourishment, which is already a risk 
factor for infected neonates. 
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PRRSV genetic determinants mediating all these effects are not known. Finding 
those determinants would be critical for rationally design vaccines or other biological 
tools (e.g. antivirals) aimed to block the above described effects in swine.  
Control of PRRSV 
There are currently no highly effective control measures for PRRSV infections.  
The virus replicates primarily in macrophages, and is able to circulate concurrently with 
the host-produced antibody.  This means that the antibody response is not sufficient for 
clearing the virus from the host (Rossow, 1998).  Eventually, the use of antibiotics may 
contribute to clear secondary bacterial infections that often accompany PRRSV and 
decrease the severity of the disease (Done, 1996).  
There are a number of commercially available vaccines against PRRSV, 
including live attenuated vaccines (LAVs) and killed virus vaccines. In general, killed 
vaccines are considered ineffective, although these vaccines  may have a limited use in 
the process of  acclimatizing of new herd animals by reducing shedding from vaccinated 
animals (Zimmerman, 2006) (see below). LAVs tend to be more effective than killed 
vaccines. These vaccines confer protective immunity that is only effective against 
homologous strains of the virus while there many different strains of PRRSV circulating 
within and among herds (Lunney, 2010).  This variability among PRRSV isolates leads 
to poor cross-protection (Zimmerman, 2006).  
Ideally, prevention of PRRSV infection originates with high in-farm biosecurity 
measures.  These preventive measures would include screening of new animals for 
PRRSV exposure, isolation of the entire facility to restrict contact with other animals, 
people, and equipment; together with disinfection and cleaning measures.  It is 
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important to notice that PRRSV is not highly stable or persistent in the environment, and 
is eliminated by hot dry conditions.  PRRSV cannot survive lipid solvents or detergents 
(Zimmerman, 2006). Therefore, disinfection is a viable way to prevent infection in a non-
infected population.  However, due to the prevalence of PRRSV it is not practical to 
attempt to create a PRRSV-negative herd and maintain it.  A large number of herds in 
the US are already infected with PRRSV and this is an obstacle for locating PRRSV-
negative swine.  
The most reasonable method for control of PRRSV infection in a herd is to 
attempt to acclimatize (expose) any incoming animals to PRRSV. Due to the cycling 
spread of PRRSV throughout a herd, all of the animals in the herd may be at different 
stages of immunity, and introducing animals that have already developed a protective 
immunity and stabilized the clinical signs of the disease is a good way to mitigate future 
losses (Zimmerman, 2006).  Introduction of gilts that have developed immunity and are 
no longer shedding the virus to the breeding herd can help to produce uninfected 
offspring.   
Since vaccination is considered the most effective way to control infectious 
disease in general, a concerted effort should be made for designing effective vaccines 
against PRRSV. Understanding mechanisms underlying PRRSV virulence is critical for 
developing effective control measures against this disease.   
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PRRSV genome 
The genome of arteriviruses consists of a positive strand of RNA which in 
PRRSV is approximately 15 kb long.  The RNA contains a poly-A tail at the 3’ end, and 
the 5’ end is capped which protects the RNA from degradation and is essential in the 
creation of infectious virus.  ORFs 1a and 1b are located towards the N-terminal half of 
the viral genome. These ORFs encode for the RNA replicase complex proteins 
(Zimmerman, 2006). ORFs 1a and 1b encode for polyproteins that are post-
translationally processed by cellular and viral proteases to yield 12 to 13 mature 
products. In the case of PRRSV nsp-1α, nsp-1β, and mainly nsp-4 are viral proteases 
that participate in the processing of the polyproteins encoded by ORFs 1a and 1b 
(Figure 1). This process has been well characterized for the prototype virus in the family 
Arteriviridae, EAV, and it is thought that the same processing takes places in PRRSV.  
Nsp-4, a serine protease, tends to be highly conserved among arteriviruses suggesting 
that key functions are maintained by this viral protein across this viral family. Nsp-9, 10, 
11, and 12 are encoded by ORF 1b via a ribosomal frameshifting (-1) (Figure 1). Nsp-9 
is the RNA-dependent RNA-polymerase and nsp-10 has a helicase motif necessary for 
functioning in RNA unwinding.  Both, nsp-9 and nsp-10 are key proteins in the genome 
replication process. In EAV nsp-11 possesses an endoribonuclease domain. These 
proteins control the copy of the virus genome as well as the creation of the subgenomic 
mRNAs that encode for PRRSV structural proteins (Fang & Snijder, 2010).  The 
function of nsp-12 is still unknown. Figure 2 shows a schematic representation of non-
structural proteins encoded by ORFs 1a and 1b. 
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Figure 1: schematic representation of PRRSV genome indicating the location of different 
open reading frames encoding for non-structural and structural proteins. ORF: open 
reading frame, GP: glycoprotein; E: envelope protein; M: matrix protein; N: nucleocapsid 
protein; RFS: ribosomal frameshift (Adapted from Fang and Snijder,  2010).  
 
Figure 2: schematic representation of polyproteins (pp) encoded by ORFs 1a and 1a/1b 
of PRRSV. 1ab pp is produced due to a -1 ribosomal frameshift. Arrows indicate sites 
cleaved by nsp-1α and nsp-1β cysteine proteases (CP) Pα and Pβ. Circles indicate sites 
cleaved by the viral protease nsp-4 serine protease (SP). nsp: non-structural proteins . 
nsp-9 is the RNA dependent RNA polymerase (RdRp). nsp-10 helicase (Hel), and nsp-11 
endoribonuclease (Ne). (Adapted from Fang and Snijder,  2010). 
The structural proteins of the virus are encoded by ORFs 2 to 7.  These ORFs 
are located towards the 3’ end of the genomic RNA (Figure 1).  The structural proteins 
include glycoproteins (GP) GP2, GP3, GP4, and GP5, which are N-glycosylated, while 
structural N protein, the nucleocapsid protein, and M protein, the matrix protein, are not 
glycosylated.  ORF 2 encodes for an additional polypeptide, protein E (envelope), an ion 
channel protein that participates in the virus entry process. N protein acts to assemble 
ORF 1a
ORF 1b
RFS
GP2
E GP3
GP4
GP5
M
N
Poly A 3’
5’ cap
Non-structural proteins Structural proteins
Pα Pβ CP                                  SP: nsp-4
Pα Pβ CP                                    SP: nsp-4                  RdRp Hel          Ne
1a pp
1ab pp
nsp: 1α 1β 2 3 4 5 6 7 8 9 10 11 12
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infectious viral particles.  M protein is the transmembrane protein, which is important for 
assembly of the virion and budding from infected cells.  GP5 is the major envelope 
glycoprotein, which acts in receptor recognition and entry into permissive cells.  GP2 
and GP4 are minor glycoproteins that are also part of the viral envelope (Zimmerman, 
2006) (Figure 3).  
 
Figure 3: Schematic representation of PRRSV virion. GP: glycoproteins, E: envelope 
proteins, and M: matrix protein.  
GP3
Lipid bilayer
GP5 M GP2a E
GP4
Nucleocapsid
Genomic RNA
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Rationale and significance 
Assessing the role of PRRSV proteins in the virus life cycle is critical for 
understanding virus pathogenesis and virus virulence. Interactions between viral and 
host proteins during virus replication within target cells may result in interference with 
cellular signaling pathways, ultimately leading to the clinical outcomes observed during 
PRRSV infection in swine. To accomplish this goal and better elucidate the interactions 
of PRRSV proteins with host cellular proteins, there is a need for reagents that would 
allow detection of those interactions. Thus, production of reagents such as antibodies to 
detect specific viral proteins is of paramount importance for these studies.  
Objective 
The objective of the work described here was to express and purify PRRSV nsp-
12 protein, one of the proteins in the virus replication complex. In turn this purified viral 
protein will be used for production of antibodies and to study host-virus protein 
interactions. 
Approach 
Non-structural protein 12 is encoded by the ORF 1b. nsp-12 is 153 amino acids 
long (Figure 4).  nsp-12 is cleaved by nsp4, which cuts at three sites of pp1ab (Figure 2) 
to yield nsp9-12.  Fang & Snijder, 2010, predicted that nsp-12 is about 152-153 amino 
acids long, depending on the strain of the virus, and that the terminal residues are Gly 
followed by Pro/Asn. The function of nsp-12 is currently unknown, and the goal of this 
research is to express and purify the protein in order to create reagents that will help to 
identify the role of the protein in the virus life cycle.  
    
Figure 4: Amino acid sequence of nsp
work. 
In the present work nsp
the N-terminus. The poly-His tag
allows binding of the expressed protein to metals (e.g. nickel or cobalt) 
purification by metal chromatography.  
forward and reverse primers
PRRSV isolate NVSL 97-7985 (pFL12, kindly provided by Dr Fernando Osorio, 
University of Nebraska-Lincoln). 
the pRSETA plasmid (Invitrogen, Carlsbad, CA) using the Infusion
(Clontech, Mountain View, CA)
control of the T7 promoter. 
transform BL21(DE3)pLysS cells
media (Invitrogen) for maximum expression of nsp
chromatography using nickel columns
followed by Coomasie blue staining and 
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-12 is expressed fused to a poly-Histidine tag located at 
 creates an ionized region in the fusion protein that 
Nsp-12 was synthesized by PCR 
 (Table 1) using as target a full-length cDNA copy of 
The amplified nsp-12 gene was inserted in
 
, where the expression of the cloned gene is under the 
 The resulting plasmid pRSETAnsp-12 was used to 
 (Invitrogen). Transformants were then grown in Magic 
-12.  Nsp-12 was purified by affinity 
, and was detected by SDS-PAGE separation 
western blotting. 
to allow 
using specific 
-frame into 
cloning system 
22 
 
Procedures and Results 
PCR amplification of PRRSV nsp-12: 
A PCR was designed to synthesize PRRSV nsp-12 using primers described in 
table 1. A 50 ul  reaction was set up as follows: 50 ng of full-length cDNA PRRSV clone 
pFL12, 5 µL of 10X Advantage PCR buffer (Clontech), 1 unit of Advantage 2 DNA 
polymerase (Clontech), 10 mM dNTPs 10 pmol of each forward and reverse primers, 
and 34.5µL ddH2O. A non-template control reaction was run as negative control.  
Cycling parameters used were 95°C for two minutes, followed by 35 cycles of 95°C for 
30 seconds, 55°C for 45 seconds, and 68°C for 60 second; finished by a final cycle of 
68°C for 3 min.  
Table 1: sequence of the primers used for PCR amplification of PRRSV NVSL 97-7895 
nsp-12 gene. 
 Primer name Sequence 
nsp-12 _for_infusion 5’-atcgatggggatccggccgccatttcacctggtac-3’ 
nsp-12 _rev_infusion 5’-gctgcagatctcgagttaattcaggcctaaagttgg-3’ 
BamHI (ggatcc) and XhoI (ctcgag) site sequences are shown in bold 
Purification of amplified nsp-12 
Amplicons of nsp-12 were resolved by agarose gel electrophoresis. A 1X-TAE 
buffer (Tris-acetate-EDTA) 1% w/v agarose containing ethidium bromide was used to 
separate the amplified DNA.  A 1kb DNA ladder (Promega, Madison, WI) was used as 
molecular size control.  Twenty-four µL samples were prepared by mixing 16 µL of 
ddH2O, 4µL of 6X loading buffer (Promega), and 4 µL of the PCR reactions. Samples 
were loaded into the gels and DNA was separated by running the sample at 90V for 1 hr 
(Figure 5). 
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Figure 5: PRRSV nsp-12 was amplified by PCR and resolved by agar gel electrophoresis 
in a 1% 1X-TAE buffer (Tris-acetate-EDTA) stained with ethidium bromide. White arrow 
indicates the presence of an amplicon of  500 bp. M: 1Kb ladder molecular weight marker 
(Invitrogen). 
 
After separation of the DNA as described above, the nsp-12 amplicon was 
extracted from the agarose gel using a QIAquick Gel Extraction Kit (Qiagen, Valencia, 
CA) according with the instructions by the manufacturers. The agarose gel was 
removed from the electrophoretic chamber and placed on top of a UV light trans-
illuminator to visualize the DNA band. A band of approximately 500 bp was excised 
from the gel using a razor blade and placed in a 1.5 ml microcentrifuge tube. The band 
was weighed and 3X volume (e.g. 100 ug = 300 µl of buffer) of Buffer QG was added to 
the tube. The tube was placed at 50°C in a heating block and incubated until the 
agarose was completely dissolved (~10 min). Then, 200 µL of isopropanol were added 
to the tube, mixed, and centrifuged for 1 min at 14,000 rpm in a bench-top 
nsp-12M
1kb
500 bp
250 bp
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microcentrifuge (Eppendorf, Hauppauge, NY).  The entire volume of the sample was 
transferred to a QIAquick column and centrifuged for 1 min at 14,000 rpm. The flow-
through was discarded and 500 µL of Buffer QG were added to the column, followed by 
centrifugation for 1 min at 14,000 rpm. The flow-through was discarded and the column 
washed once by adding 750 µL of Buffer PE followed by centrifugation for 1 min at 
14,000 rpm. The flow-through was discarded and the column centrifuged again for 1 
min at 14,000 rpm to remove residual ethanol. DNA was eluted from the columns using 
50 µl of Buffer EB and centrifuged for 1 min at 14,000 rpm. Recovered DNA was ready 
for cloning into pRSET A (Invitrogen) (Figure 6). 
 
Figure 6: Invitrogen’s pRSET diagram. PT7: T7 promoter. RBS: ribosomal binding site. 
ATG: codon encoding for methionine. 6xHis: histidine tag. Xpress Eptope: synthetic 
epitope tag. EK: enterokinase cleavage site. MCS: multiple cloning site. Stop: stop 
codon. Blue circles denote the restriction endonucleases used here. 
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Cloning of nsp-12 gene into pRSET A vector 
For cloning nsp-12 into pRSET A the In-Fusion® PCR Cloning System 
(Clontech) was used. This system allows the ends of the amplified DNA (i.e. nsp-12) to 
“fuse” to the homologous ends of a linearized vector.  The 3' and 5' regions of homology 
were generated by adding 15 bp extensions to both PCR primers (Table 1) that 
precisely match the ends of linearized pRSET A.  The linearized vector was combined 
with nsp-12 amplicon and the In-Fusion® enzyme included in the kit converts the 
double-stranded extensions into single-stranded DNA and fuses these regions to the 
corresponding ends of the linearized pRSET A.  
The pRSET A plasmid(2.9 Kb) was digested with restriction endonucleases 
BamHI and XhoI in a 20 µl reaction. The reaction was set as follows: 10 µl of pRSET A 
(390 ng/ul), 2 µl of 10X NEB buffer 2 (New England Biolabs, Ipswich, MA), 0.5 µl of 
100X BSA, 1 µl of BamHI enzyme (20,000U/mL) (New England Biolabs), 1 µl of XhoI 
enzyme (20,000U/mL) (New England Biolabs), and 5.5 µl ddH2O. The reaction was 
then incubated at 37°C in a water bath for 2 hr. After digestion, pRSET A linearized 
DNA was resolved in a 1% agarose-TAE-ethidium bromide gel, and a 2.9 Kb band 
excised and purified from the gel using QIAquick Gel Extraction Kit (Qiagen) as 
described above. 
After purification of the digested vector (pRSET A), a ligation reaction was set up 
using the In-Fusion® PCR Cloning System (Clontech).   The purified insert and vector 
were mixed in a 2:1 ratio using the following equation: 
 	

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The reaction was set as follows: 4µL 5X In-fusion Reaction Buffer, 2µL In-fusion 
enzyme, 7µL vector, 2µL insert, 5µL dH2O, and 30µL TE Buffer. The reaction was 
incubated for 30 min at 250C. After incubation the In-fusion reaction was used to 
transform chemically competent TOP10 E.coli cells (Invitrogen) via heat-shock 
transformation.  The In-fusion reaction was added to the cells and incubated on ice for 
30 minutes, for 40 seconds at 42°C, followed by incubation on ice for 2 min.  To recover 
the cells 250 µL of SOC media (Invitrogen) was added to the cells and incubated at 
37°C with shaking for 1 hour.  Transformed cells were then plated in terrific broth agar 
plates containing ampicillin and incubated overnight at 37°C.  
Recovery of pRSETAnsp-12 
Four ampicillin resistant colonies were picked from the plates and transferred to 
5mL terrific broth ampicillin media.  The cultures were incubated at 37°C with shaking 
overnight. Growth of bacteria was detected by observing an increased turbidity of the 
culture media. The bacterial culture was then spun down in bench-top centrifuge at 
4000rpm for 15 minutes to produce a cell pellet. Supernatant was discarded and 
plasmid DNA was extracted from the cells using the QIASpin Miniprep Kit (Qiagen) 
according with the instructions provided by the manufacturer. The cell pellet was 
resuspended in 250µL of Buffer P1 (kept at 40C before use), this is a cell lysis buffer 
that contains RNAase. The suspension was then transferred to a microcentrifuge tube 
and 250µL of Buffer P2 (high pH buffer) were and mixed thoroughly by inverting the 
tube 4-6 times. After mixing, 350µL of Buffer N3 (low pH buffer) were added and rapidly 
and thoroughly mixed. The mixture was then centrifuged for 10 min at 14,000rpm to 
separate cellular debris from the aqueous phase where plasmid DNA is in solution. The 
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supernatant was then applied to the QIAPrep spin columns by decanting and the tube 
was centrifuged for 30 sec at maximum speed.  The flow-through was discarded and 
the spin column was washed by adding 0.75mL of Buffer PE containing ethanol and 
centrifuged again for 30 sec at maximum speed. The flow-through was discarded and 
the tube was centrifuged again for 1 min at maximum speed to remove the residual 
wash buffer. Plasmid DNA was recovered by placing the column on top of a clean 1.5 
mL microcentrifuge tube, adding 50 µL Buffer EB (elution buffer) to the center of the 
column, and spinning 1 min at maximum speed.   
Analysis of recovered plasmid DNA 
Recovered plasmids were digested with restriction endonucleases BamHI and 
XhoI to determine if they contained an insert of the proper size (nsp-12, 500 bp). The 
restriction reaction was set as follows:  5µL of each extracted plasmid DNA, 2µL of 10X 
NEB Buffer 2 (New England Biolabs), 0.5mL BSA (100X), 1µL BamHI (20,000U/mL), 
1µL Xho1 (20,000U/mL), and 10.5µL of ddH2O.  This mixture was incubated at 37°C in 
water bath for 2 hr.  After digestion, DNA was resolved in a 1% agarose-TAE-ethidium 
bromide gel as described above (Figure 7). 
To assess the fidelity of the cloned gene, plasmid DNA showing the expected 
restriction pattern were submitted for sequencing (Genewiz, South Plainfield, NJ). 
Obtained sequences were analyzed using the Bioedit software.  
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Figure 7: Restriction analysis (BamHI and XhoI digestion) of plasmids DNA extracted 
from isolated E.coli colonies. Clone number 3 was excised by both restriction enzymes 
and produced two definite bands of 2.9 kb (top band) and 500 bp (bottom band). DNA 
was resolved by agar gel electrophoresis in a 1% 1X-TAE buffer (Tris-acetate-EDTA) 
stained with ethidium bromide. M: 1 Kb ladder molecular weight marker (Invitrogen). 
Scaling up PRSETAnsp12 plasmid concentration 
Once fidelity of the inserted nsp-12 gene into pRSET A was determined, the 
concentration of plasmid DNA was increased by using the Hispeed Plasmid Maxi Kit 
(Qiagen).  E.coli harboring pRSETAnsp-12 was cultured in 150 ml of terrific broth media 
containing ampicillin overnight at 37°C with shaking. After incubation the culture was 
centrifuged at 4,000 rpm for 15 min. Supernatant was decanted and the bacterial pellet 
was resuspended in 10mL of Buffer P1 (kept at 40C) incubating for 5 minutes at room 
temperature. After thorough mixing by vortexing to resuspend the bacterial pellet, 10 ml 
of buffer P2 were added and mixed by repeated inversions of the flask.  To neutralize 
1 2 3 4M
500 bp
29 
 
the activity of buffer P2, 10 ml of Buffer P3 were added, mixed gently by inversion. The 
mixture was transferred to QIAfilter cartridge and incubated at room temperature for 10 
minutes. In the meantime a HISpeed-tip 500 column was equilibrated by adding 10mL 
Buffer QBT and allowed to drain for 10 min. The content of the QIAfilter cartridge was 
transferred to the equilibrated a HISpeed-tip 500 column for binding of the DNA to the 
silica filter. After the flow through was discarded the column was washed one with 60 ml 
of Buffer QC. DNA was then recovered by eluting with 15 ml of Buffer QF. Plasmid DNA 
was then precipitated by adding 10.5 ml (0.7 volumes) of isopropanol and incubating at 
room temperature for 5 min. The eluate/isopropanol mixture was run through a 
QIAprecipitator and flow-through was discarded. The QIAprecipitator was then washed 
twice with 2 ml of 70% ethanol and DNA recovered by adding 1ml of Buffer TE.  
Recovered DNA was then submitted again for sequencing (Genewiz). 
Expression of PRRSV nsp-12 
 E. coli BL21(DE3)pLysS chemically competent cells (Invitrogen) were 
transformed with pRSETAnsp-12 as previously described in this work.  Two colonies 
were picked from the terrific broth agar ampicillin plates and transferred to 5mL of terrific 
broth containing 50 µg/ml of ampicillin and 35 µg/ml of chloramphenicol and grown with 
shaking overnight at 37°C. Chloramphenicol selects for maintenance of the pLysS 
plasmid required for T7 lysozyme expression and ampicillin selects for the pRSET A 
plasmid. After incubation, 150 µL of the culture were then added to 150 mL of 
Invitrogen’s Magic Media. The culture was incubated for 18 hr at 370C, after which it 
was centrifuged at 4,000rpm for 30 min and the supernatant was discarded.  The pellet 
containing expressed nsp-12 was kept at -20°C prior to lysis.  
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 To extract nsp-12, BL21 cells pellet was thawed on ice and 20mL of CellLytic B 
buffer (Sigma, St Louis, MO) containing 100µL of protease inhibitor (Sigma) was added 
per 1 g of cells. The pellet was resuspended by pipetting and vortexing, and incubated 
at 37°C for 15 min with shaking.  The lysate was then transferred to 1.5 ml 
microcentrifuge tubes and centrifuged for 30 min at 13,200rpm.  Supernatant was 
collected and stored at -20°C.  
To determine nsp-12 expression a NuPAGE® Novex 12% Bis-Tris Gel 
(Invitrogen) was run. Samples were run under reducing conditions by mixing 2.5 µL of 
NuPAGE® LDS Sample Buffer (4X), 1µL of NuPAGE® Reducing Agent (10X), and  6.5 
µL protein lysate. Separation of proteins was done in 1X SDS Running Buffer (50 ml 
20X NuPAGE® MES SDS Running Buffer in 950 ml of ddH2O). A molecular size 
marker was run next to the cell lysates (Novex® Sharp Pre-stained Protein Standard, 
Invitrogen). The gel was run at 200V for 35 min. After separation the gel was transfer to 
a clean tray and stained with Coomasie blue (SimplyBlue Self Stain, Invitrogen) (Figure 
8). 
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Figure 8. BL21 cell protein lysates were separated by SDS-PAGE using a NuPAGE® 
Novex 12% Bis-Tris Gel (Invitrogen) and stained with SimplyBlue Self Stain (Invitrogen). 
M: molecular size marker expressed in kDa. 
 
Detection of nsp-12 by western immunoblots 
A SDS-PAGE was set and run under the conditions described above. After the 
run, proteins were transferred to a PVDF (polyvinylidene difluoride) membrane 
(Invitrogen).  To perform the transfer, the gel is layered next to the PVDF membrane 
and placed in a voltage gradient perpendicular to the gel (X Cell II Blot Module, 
Invitrogen). Negatively charged molecules (i.e. proteins) will migrate out from the gel, 
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move towards the positive electrode, and get deposited on the membrane. The transfer 
buffer for reducing conditions was set by combining  50 mL of NuPAGE® Transfer 
Buffer (20X), 1 mL NuPAGE® Antioxidant, Methanol* 100 mL, and 849 ml of ddH2O. 
Before transferring the PVDF membrane was activated in methanol for 30 seconds and 
then transferred to 100 ml of transfer buffer. The transfer was run for 70 min at 30V, 
170mVa using the X Cell II Blot Module (Invitrogen). 
After transfer the PVDF membrane was washed three times for 5 minutes with 
ddH2O. The membrane was then blocked for 90 minutes in blocking buffer 
(WesternBreeze Chemiluminescent immunodetection kit, Invitrogen) containing 5mL 
water, 2mL Blocker/Diluent A, and 3mL Blocker/Diluent B. After blocking, the membrane 
was washed with ddH2O twice for 5 min. The membrane was incubated with the 
primary antibody, an anti-His tag monoclonal antibody diluted 1:2000 in a buffer 
containing 7mL of ddH2O, 2mL of  Blocker/Diluent A, and 1mL Blocker/Diluent B for 60 
min at room temperature. The membrane was then washed three times with antibody 
wash buffer containing 10mL of antibody wash, and 150mL of ddH2O, for 5 min at room 
temperature. After washing, the membrane was incubated with the secondary anti-
mouse antibody in a buffer containing 10 ml of secondary antibody solution and 4 µL of 
goat anti-mouse alkaline phosphatase conjugated antibody for 35 min. The membrane 
was washed twice for 5 min with ddH2O to remove unbound secondary antibody. Using 
a clean pipette 2.5 ml of alkaline phosphatase Chemiluminescent substrate were placed 
on top of the PVDF membrane and the reaction was allowed to proceed for 5 min. 
Excess substrate was removed with a paper filter without allowing the membrane to dry 
out. The membrane was then covered with a transparency and exposed to a Kodak X-
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OMAT AR film for several minutes. The substrate-enzyme reaction releases light that is 
captured by the X-ray film (see below). 
Purification of nsp-12 
Chemically competent One Shot BL21 (DE3) pLysS E. coli (Invitrogen) cells were 
transformed with 10 ng of pRSETAnsp-12 plasmid encoding PRRSV nsp-12, cultured in 
MagicMedia (Invitrogen) for 21 hours at 37°C with shaking, and harvested by 
centrifugation at 4,000 rpm for 15 minutes. Cell pellets were then treated with CelLytic 
buffer (Sigma Aldrich, St. Louis, MO) according to the manufacturer’s large scale 
extraction protocol. For His-tagged protein purification, cell lysates were applied to 
HisPur Cobalt Spin Columns (Thermo Fisher Scientific, Rockford, IL). Briefly, the 3mL 
capacity spin columns were equilibrated at room temperature and protein lysates were 
thawed on ice for 30 min before purification.  The bottom plug at the bottom of the 
column and storage buffer was allowed to drain out by gravity.  The spin column was 
equilibrated by adding two volumes of resin bed in 6 mL of Equilibration/Wash Buffer 
with the cap at the bottom of the column in place. The column was allowed to sit for 4 
min before use.  After this equilibration step, columns were inverted a few times and the 
Equilibration/Wash Buffer was drained from the columns for 4 min.  To purify nsp-12, 
the protein lysate was mixed with an equal volume of Equilibration/Wash Buffer and 
vortexed.  The bottom of the column was capped and the protein lysate was applied to 
the spin column. The spin column was inverted several times to mix and incubated on 
ice for 80 min under vigorous shaking. During this incubation, the spin column was 
shaken vigorously by hand every 2 to 3 min to ensure that resins do not form a packed 
pellet. The spin column was then placed on the top a 15 ml centrifuge tube and drained 
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by removing the bottom cap and loosening the top cap. The flow through was collected, 
labeled Collection 1 and kept on ice.  The resin in the column was washed with 2 
volumes of Equilibration/Wash Buffer and incubated for 4 min. The flow-through was 
collected in a new 15 ml centrifuge tube and labeled Wash 1. The process was 
repeated two more times and Wash 2 and Wash 3 were collected. His-tagged nsp-12 
was eluted from the resin by adding one resin-bed volume of Elution Buffer and 
incubating for 4 min.  After incubation the flow-through was collected in 15 ml centrifuge 
tube and labeled Elution 1. The same process was repeated two more times and 
Elutions 2 and 3 were collected. All fractions were stored at -200C. PRRSV nsp-12 has 
a molecular size of 17 kDa. The protein purified here was expressed as a His-tagged 
fusion protein with a molecular mass of 21 kDa (Figure 9). 
 
Figure 9: Amino acid sequence of PRRSV nasp-12 fusion protein expressed in this work. 
In red is the fused sequence that includes 6x-His, Express® epitope, and enterokinase 
cleavage site. 
 
Collected fractions were analyzed on a 10% NuPage Novex Bis-Tris gel 
(Invitrogen) using a discontinuous SDS-PAGE system as described above (Figure 10). 
Western blots were performed using PVDF membranes (Invitrogen) and a His-Tag 
antibody (Novagen, EMD Biosciences, Madison, WI) as described above. Reactions 
were developed using alkaline phosphatase labeled goat anti-mouse IgG antibody with 
the WesternBreeze Chemiluminescent Detection Kit (Invitrogen). The purified proteins 
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSGRHFTWYQL
XSYASYIRVPVNSTVYLDPCMGPALCNRRVVGSTHWGADLAVTPYDYGAKII
LSSAYHGEMPPGYKILACAEFSLDDPVRYKHTWGFESDTAYLYEFTGNGEDW
EDYNDAFRARQ KGKIYKATATSMRFHFPPGPVIEPTLGLN
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were desalted twice using 7K MWCO Zebra Spin Desalting Columns (Thermo Fisher 
Scientific). Protein concentration was determined by BCA Protein Assay (Thermo Fisher 
Scientific) against known standards at OD of 595 nm using NanoDrop instrument 
(Thermo Scientific NanoDrop Products, Wilmington, DE) (Figure 11).  
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Figure 10. Purification of His-tagged PRRSV nsp-12. SDS-PAGE electrophoresis stained 
with Simple Blue (invitrogen). M: molecular size markers expressed in kDa. C1: collection 
1. W: washes. E: ellutions. Arrow indicates nsp-12 His-tagged fusion with a molecular 
size of 21 kDa. 
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Figure 11. Westen immunoblot showing His-tagged nsp-12. M: molecular size markers 
expressed in kDa. C1: collection 1. W: washes. E: ellutions. Arrow indicates nsp-12 His-
tagged fusion with a molecular size of 21 kDa. 
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Summary 
 Nsp-12 from PRRSV isolate NVSL 97-7985 was synthesized by PCR 
amplification, cloned into E. coli expression vector pRSET A, and expressed in E. coli 
BL21 (DE3) pLysS.  PRRSV nsp-12 was purified by affinity chromatography and its 
purity verified by SDS-PAGE and Western blot.  A variety of molecular techniques were 
used and successfully adjusted during the course of this work, including DNA 
amplification, protein expression, protein separation, and protein purification.  Overall 
the objective of this work was fulfilled. 
PRRSV nsp-12 will be used for production of antibodies. These antibodies 
against nsp-12 are critical for studies such as protein-protein interactions between viral 
and host proteins. This work was highly significant and will make attaining those goals 
possible. 
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Outlook 
Porcine Reproductive and Respiratory Syndrome Virus is an extremely prevalent 
and economically significant disease for the swine industry.  Although much is known 
about Equine Arteritis Virus the prototype virus in the family Arteriviridae there is limited 
information about the biology of PRRSV.  One of the more limiting aspects in the fight 
against PRRSV is that many of the functions of the viral proteins are unknown.  The 
advantage of purifying these proteins is to create reagents that can be used in research 
such as, determining the function of nsp-12 in PRRSV cycle.  With the production of an 
antibody to PRRSV nsp-12, it may soon be possible to discover functions such as, 
which cellular proteins interact with nsp-12 during infection.  It is hypothesized that nsp-
12 may be involved in host infection and/or virus replication, and the availability of a 
reagent that binds specifically to nsp-12 can pave the way for future experiments in 
identification and possibly blocking of the protein’s function.  Furthermore, the 
successful purification of this protein may serve as a protocol for the purification of other 
little-researched PRRSV proteins.  
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